First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo

Dermatology Times·Jul 9

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A phase 2 trial of a topical pan-jak inhibitor called LNK01004 for vitiligo has begun, with the first patient dosed. Other treatments for various skin and eye conditions are also in clinical trials, including a phase 2 trial for molluscum contagiosum and a phase 3 study for common warts. Additionally, a treatment for neurotrophic keratitis has advanced to phase 2 after receiving dual FDA designations.

Full coverage

First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy

CGTLive®·Jul 7

First Patients Dosed in Alphyn Biologics' Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum

PR Newswire·Feb 18

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Ophthalmology Times Europe·Jun 2

Milestone Alert: First Patient Dosed in Phase 3 Study of YCANTH for Common Warts

The Dermatology Digest·Jan 7

FDA grants TearSolutions' NK peptide therapy two FDA designations

Eyes On Eyecare·Jun 4

EyeWorld Weekly, February 13, 2026

EyeWorld·Feb 13

Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia

BioSpace·Apr 2

Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum

Dermatology Times·Feb 19

View original report at Dermatology Times ↗

Fetching the latest headlines…